First Dutch has acquired the shares of Intravacc from the Dutch government. Since its privatization in 2013, Intravacc has increasingly focused on collaboration with the pharmaceutical industry and NGOs. The Dutch government no longer deemed it necessary to retain ownership and offered its shares for sale. After an extensive and careful search, First Dutch was given the exclusive opportunity to complete the transaction. Peter Goedvolk, owner and CEO of First Dutch, is proud of this acquisition: “In 2016, we began acquiring shares in TNO Bedrijven BV and have since built a solid position in the life & biosciences world. This helped shape the Ministry of Health, Welfare and Sport’s decision to do business with us. It is also explicitly our plan to keep Intravacc headquartered in the Netherlands. We are called First Dutch for a reason. Intravacc has over a hundred years of experience and represents Dutch glory, which suits us well. Moreover, it contributes to our mission of social return.”
Intravacc will become part of the life & biosciences platform of First Dutch Innovations. Here, it can strengthen its market position and grow more rapidly. Additionally, it will further open its technology to partners developing their own vaccines. Intravacc will increasingly focus on providing services for vaccines in developing countries. Alongside Intravacc, InnoGI Technologies (formerly TIM) is active in the (pre-)clinical phase of in vitro research into oral medicines. With the addition of Intravacc to the portfolio, the companies can reinforce each other. As an international contract development and manufacturing organization (CDMO) with its origins and foundation in the Netherlands, Intravacc develops new and improved vaccines for the pharmaceutical industry and NGOs. Its mission is to reduce human diseases through innovative vaccine technology. Intravacc was established in 2013 from the Dutch Vaccine Institute (NVI) and has years of experience in translational vaccinology.